Orthocell (OCC) Stock Overview
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OCC from our risk checks.
OCC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Orthocell Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.96 |
| 52 Week High | AU$1.70 |
| 52 Week Low | AU$0.85 |
| Beta | -0.34 |
| 1 Month Change | 0.52% |
| 3 Month Change | -9.81% |
| 1 Year Change | -28.52% |
| 3 Year Change | 147.44% |
| 5 Year Change | 96.94% |
| Change since IPO | 168.06% |
Recent News & Updates
Recent updates
We're Hopeful That Orthocell (ASX:OCC) Will Use Its Cash Wisely
Apr 04
Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Sep 09It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year
Oct 25We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth
Nov 16We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate
Jul 29Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans
Mar 23We're Not Worried About Orthocell's (ASX:OCC) Cash Burn
Dec 08Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
May 31Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Feb 15How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?
Dec 24Shareholder Returns
| OCC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 3.2% | -4.4% | 1.4% |
| 1Y | -28.5% | -44.6% | 10.2% |
Return vs Industry: OCC exceeded the Australian Biotechs industry which returned -44.6% over the past year.
Return vs Market: OCC underperformed the Australian Market which returned 10.2% over the past year.
Price Volatility
| OCC volatility | |
|---|---|
| OCC Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: OCC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: OCC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Paul Anderson | orthocell.com |
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications.
Orthocell Limited Fundamentals Summary
| OCC fundamental statistics | |
|---|---|
| Market cap | AU$259.10m |
| Earnings (TTM) | -AU$12.48m |
| Revenue (TTM) | AU$9.33m |
Is OCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCC income statement (TTM) | |
|---|---|
| Revenue | AU$9.33m |
| Cost of Revenue | AU$3.38m |
| Gross Profit | AU$5.95m |
| Other Expenses | AU$18.43m |
| Earnings | -AU$12.48m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 63.77% |
| Net Profit Margin | -133.78% |
| Debt/Equity Ratio | 0% |
How did OCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/26 17:13 |
| End of Day Share Price | 2026/02/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orthocell Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shane Storey | Canaccord Genuity |